摘要
目的 观察培门冬酶联合化疗治疗难治性淋巴瘤的效果.方法 回顾性分析28例难治性淋巴瘤患者接受含培门冬酶化疗方案治疗的结果.结果 28例患者中位年龄36岁,治疗前疾病状态为部分缓解（PR）4例,疾病稳定（SD）6例,疾病复发或疾病进展（PD）18例,治疗后患者完全缓解（CR）5例,PR 15例,SD 4例,PD 4例,总有效（CR＋PR）率为71.4％.16例T细胞性淋巴瘤患者治疗有效率达81.3％（13/16）.10例弥漫大B细胞淋巴瘤患者治疗有效率达60.0％（6/10）.治疗前无骨髓浸润者或无乳酸脱氢酶升高者治疗有效率更高.主要不良反应为骨髓抑制、消化道反应、凝血异常.结论 培门冬酶联合化疗方案可作为拯救性治疗难治性淋巴瘤的选择之一.
Objective To evaluate the efficacy and safety of PEG-asparaginase based regimen for refractory lymphoma.Methods The retrospective analysis of twenty-eight patients who received PEGasparaginase based regimen.Results Twenty-eight patients were eligible for treatment-response evaluation.The median age was 36 years old.Before treatment,4 patients were in partial response,6 patients in stable disease,and 18 patients in progressive disease.After treatment,5 patients were in complete response （CR）,15 patients were in partial response （PR）,4 patients were in stable disease,and 4 patients were in progressive disease.The overall response （CR＋PR） rate was 71.4 %.The treatment effective rate was 81.3 % （13/16） in 16 cases of T-cell lymphoma and 60.0 % （6/10） in diffuse large B-cell lymphoma.The treatment rate was higher for patients without bone marrow infiltration or without increased dehydrogenase.The major adverse events were myelosuppression,gastrointestinal reaction and coagulopathy.Conclusion PEG-asparaginase based regimen was one of the options of salvage therapy for refractory lymphoma.
出处
《白血病．淋巴瘤》
CAS
2014年第10期611-615,共5页
Journal of Leukemia & Lymphoma
关键词
难治性淋巴瘤
培门冬酶
化疗
联合
Refractory lymphoma
PEG-asparaginase
Chemotherapy
Combination
